TEST BANK
Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition
Author: Teri Moser Woo and Wendy L. Wright
TABLE OF CONTENT
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber ................................................................... 4
Chapter 2. Review of Basic Principles of Pharmacology..................................................................................... 5
Chapter 3. Rational Drug Selection ................................................................................................................. 11
Chapter 4. Legal and Professional Issues in Prescribing ................................................................................. 14
Chapter 5. Adverse Drug Reactions ................................................................................................................ 16
Chapter 6. An Introduction to Pharmacogenomics.......................................................................................... 19
Chapter 7. Nutrition and Nutraceuticals ......................................................................................................... 22
Chapter 8. Herbal Therapies........................................................................................................................... 28
Chapter 9. Cannabis....................................................................................................................................... 31
Chapter 10. Pharmacoeconomics ................................................................................................................... 35
Chapter 11. Drugs Affecting the Autonomic Nervous System ......................................................................... 38
Chapter 12. Drugs Affecting the Central Nervous System............................................................................... 45
Chapter 13. Drugs Affecting the Cardiovascular and Renal Systems ............................................................... 53
Chapter 14. Drugs Affecting the Respiratory System ...................................................................................... 61
Chapter 15. Drugs Affecting the Hematological System ................................................................................. 65
Chapter 16. Drugs Affecting the Immune System: Vaccines and Immunoglobulins......................................... 69
Chapter 17. Drugs Affecting the Immune System: Immunomodulators .......................................................... 75
Chapter 18. Drugs Affecting the Gastrointestinal System ............................................................................... 77
Chapter 19. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs.................. 80
Chapter 20. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs ............................ 83
Chapter 21. Drugs Affecting the Reproductive System ................................................................................... 86
Chapter 22. Drugs Affecting the Bones and Joints .......................................................................................... 92
Chapter 23. Drugs Affecting the Integumentary System ................................................................................. 96
Chapter 24. Drugs Used to Treat Bacterial Infections ................................................................................... 101
Chapter 25. Drugs Used to Treat Viral, Fungal, and Protozoal Infections...................................................... 105
Chapter 26. Drugs Used to Treat Inflammatory Processes ............................................................................ 108
Chapter 27. Drugs Used to Treat Eye and Ear Disorders ............................................................................... 111
Chapter 28. Anemia ..................................................................................................................................... 113
Chapter 29. Anxiety and Depression ............................................................................................................ 116
Chapter 30. Attention Deficit-Hyperactivity Disorder ................................................................................... 120
Chapter 31. Asthma and Allergy .................................................................................................................. 122
Chapter 32. Chronic Obstructive Pulmonary Disease .................................................................................... 125
,Chapter 33. Contraception ........................................................................................................................... 127
Chapter 34. COVID-19: Acute and Chronic .................................................................................................. 130
Chapter 35. Dermatological Conditions........................................................................................................ 134
Chapter 36. Diabetes Management .............................................................................................................. 138
Chapter 37. Gastroesophageal Reflux and Peptic Ulcer Disease ................................................................... 146
Chapter 38. Headaches ................................................................................................................................ 149
Chapter 39. Heart Failure ............................................................................................................................. 153
Chapter 40. HIV Disease and Acquired Immunodeficiency Syndrome ........................................................... 158
Chapter 41. Menopausal Hormone Therapy ................................................................................................. 161
Chapter 42. Hyperlipidemia .......................................................................................................................... 164
Chapter 43. Hypertension ............................................................................................................................ 169
Chapter 44. Hyperthyroidism and Hypothyroidism ....................................................................................... 174
Chapter 45. Obesity ..................................................................................................................................... 177
Chapter 46. Pain Management: Acute and Chronic Pain ............................................................................... 181
Chapter 47. Pneumonia ................................................................................................................................ 185
Chapter 48. Sexually Transmitted Diseases and Vaginitis............................................................................. 187
Chapter 49. Substance Use Disorders........................................................................................................... 190
Chapter 50. Tuberculosis ............................................................................................................................. 195
Chapter 51. Upper Respiratory Tract Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa .......... 197
Chapter 52. Urinary Tract Infections............................................................................................................. 200
Chapter 53. Women as Patients .................................................................................................................... 203
Chapter 54. Men as Patients ......................................................................................................................... 207
Chapter 55. Pediatric Patients ...................................................................................................................... 209
Chapter 57. Geriatric Patients ...................................................................................................................... 213
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. The benefits to the patient of having an advanced practice registered nurse (APRN)
prescriber include:
A. Nurses know more about pharmacology than other prescribers because they take
it both in their basic nursing program and in their APRN program.
B. Nurses care for the patient from a holistic approach and include the patient
in decision-making regarding their care.
C. APRNs are less likely to prescribe narcotics and other controlled substances.
D. APRNs are able to prescribe independently in all states, whereas a physician’s
assistant needs to have a physician supervising their practice.
ANS: B PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. The process for choosing an effective drug for a disorder includes:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration guidelines for prescribing
ANS: B PTS: 1
5. Nonintentional nonadherence of drug therapy may occur due to:
A. Belief that medication does not work
B. Adverse drug reactions
C. Chronic conditions that require daily therapy
D. Forgetfulness or distraction
ANS: D PTS: 1
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch02
Chapter 2. Review of Basic Principles of Pharmacology
MULTIPLE CHOICE
1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is
critical to prescribing because:
A. Distribution of drugs to target tissue may be affected.
B. The solubility of the drug will not match the site of absorption.
C. There will be less free drug available to generate an effect.
D. Drugs bound to albumin are readily excreted by the kidneys.
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little, if any, desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be the:
A. Kidneys
B. Lungs
C. Bile and feces
D. Skin
ANS: B PTS: 1
4. A major disadvantage to IV administration is that:
A. First-pass metabolism is eliminated.
B. Needles and sterility are required.
C. Absorption of the drug cannot be slowed after administration.
D. It is significantly more expensive than other routes.
ANS: C PTS: 1
5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge
of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render
it biologically inactive. This is best characterized as a(n):
Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition
Author: Teri Moser Woo and Wendy L. Wright
TABLE OF CONTENT
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber ................................................................... 4
Chapter 2. Review of Basic Principles of Pharmacology..................................................................................... 5
Chapter 3. Rational Drug Selection ................................................................................................................. 11
Chapter 4. Legal and Professional Issues in Prescribing ................................................................................. 14
Chapter 5. Adverse Drug Reactions ................................................................................................................ 16
Chapter 6. An Introduction to Pharmacogenomics.......................................................................................... 19
Chapter 7. Nutrition and Nutraceuticals ......................................................................................................... 22
Chapter 8. Herbal Therapies........................................................................................................................... 28
Chapter 9. Cannabis....................................................................................................................................... 31
Chapter 10. Pharmacoeconomics ................................................................................................................... 35
Chapter 11. Drugs Affecting the Autonomic Nervous System ......................................................................... 38
Chapter 12. Drugs Affecting the Central Nervous System............................................................................... 45
Chapter 13. Drugs Affecting the Cardiovascular and Renal Systems ............................................................... 53
Chapter 14. Drugs Affecting the Respiratory System ...................................................................................... 61
Chapter 15. Drugs Affecting the Hematological System ................................................................................. 65
Chapter 16. Drugs Affecting the Immune System: Vaccines and Immunoglobulins......................................... 69
Chapter 17. Drugs Affecting the Immune System: Immunomodulators .......................................................... 75
Chapter 18. Drugs Affecting the Gastrointestinal System ............................................................................... 77
Chapter 19. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs.................. 80
Chapter 20. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs ............................ 83
Chapter 21. Drugs Affecting the Reproductive System ................................................................................... 86
Chapter 22. Drugs Affecting the Bones and Joints .......................................................................................... 92
Chapter 23. Drugs Affecting the Integumentary System ................................................................................. 96
Chapter 24. Drugs Used to Treat Bacterial Infections ................................................................................... 101
Chapter 25. Drugs Used to Treat Viral, Fungal, and Protozoal Infections...................................................... 105
Chapter 26. Drugs Used to Treat Inflammatory Processes ............................................................................ 108
Chapter 27. Drugs Used to Treat Eye and Ear Disorders ............................................................................... 111
Chapter 28. Anemia ..................................................................................................................................... 113
Chapter 29. Anxiety and Depression ............................................................................................................ 116
Chapter 30. Attention Deficit-Hyperactivity Disorder ................................................................................... 120
Chapter 31. Asthma and Allergy .................................................................................................................. 122
Chapter 32. Chronic Obstructive Pulmonary Disease .................................................................................... 125
,Chapter 33. Contraception ........................................................................................................................... 127
Chapter 34. COVID-19: Acute and Chronic .................................................................................................. 130
Chapter 35. Dermatological Conditions........................................................................................................ 134
Chapter 36. Diabetes Management .............................................................................................................. 138
Chapter 37. Gastroesophageal Reflux and Peptic Ulcer Disease ................................................................... 146
Chapter 38. Headaches ................................................................................................................................ 149
Chapter 39. Heart Failure ............................................................................................................................. 153
Chapter 40. HIV Disease and Acquired Immunodeficiency Syndrome ........................................................... 158
Chapter 41. Menopausal Hormone Therapy ................................................................................................. 161
Chapter 42. Hyperlipidemia .......................................................................................................................... 164
Chapter 43. Hypertension ............................................................................................................................ 169
Chapter 44. Hyperthyroidism and Hypothyroidism ....................................................................................... 174
Chapter 45. Obesity ..................................................................................................................................... 177
Chapter 46. Pain Management: Acute and Chronic Pain ............................................................................... 181
Chapter 47. Pneumonia ................................................................................................................................ 185
Chapter 48. Sexually Transmitted Diseases and Vaginitis............................................................................. 187
Chapter 49. Substance Use Disorders........................................................................................................... 190
Chapter 50. Tuberculosis ............................................................................................................................. 195
Chapter 51. Upper Respiratory Tract Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa .......... 197
Chapter 52. Urinary Tract Infections............................................................................................................. 200
Chapter 53. Women as Patients .................................................................................................................... 203
Chapter 54. Men as Patients ......................................................................................................................... 207
Chapter 55. Pediatric Patients ...................................................................................................................... 209
Chapter 57. Geriatric Patients ...................................................................................................................... 213
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. The benefits to the patient of having an advanced practice registered nurse (APRN)
prescriber include:
A. Nurses know more about pharmacology than other prescribers because they take
it both in their basic nursing program and in their APRN program.
B. Nurses care for the patient from a holistic approach and include the patient
in decision-making regarding their care.
C. APRNs are less likely to prescribe narcotics and other controlled substances.
D. APRNs are able to prescribe independently in all states, whereas a physician’s
assistant needs to have a physician supervising their practice.
ANS: B PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. The process for choosing an effective drug for a disorder includes:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration guidelines for prescribing
ANS: B PTS: 1
5. Nonintentional nonadherence of drug therapy may occur due to:
A. Belief that medication does not work
B. Adverse drug reactions
C. Chronic conditions that require daily therapy
D. Forgetfulness or distraction
ANS: D PTS: 1
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e Ch02
Chapter 2. Review of Basic Principles of Pharmacology
MULTIPLE CHOICE
1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is
critical to prescribing because:
A. Distribution of drugs to target tissue may be affected.
B. The solubility of the drug will not match the site of absorption.
C. There will be less free drug available to generate an effect.
D. Drugs bound to albumin are readily excreted by the kidneys.
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little, if any, desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be the:
A. Kidneys
B. Lungs
C. Bile and feces
D. Skin
ANS: B PTS: 1
4. A major disadvantage to IV administration is that:
A. First-pass metabolism is eliminated.
B. Needles and sterility are required.
C. Absorption of the drug cannot be slowed after administration.
D. It is significantly more expensive than other routes.
ANS: C PTS: 1
5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge
of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render
it biologically inactive. This is best characterized as a(n):
